Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
about
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerA phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancerA phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer.Emerging anticancer potentials of goniothalamin and its molecular mechanisms.Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.Weekly paclitaxel infusion as salvage therapy in ovarian cancer.American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitorsTopoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeuticsSafety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.Euphorbia mauritanica and Kedrostis hirtella extracts can induce anti-proliferative activities in lung cancer cells.A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.Ganoderma lucidum targeting lung cancer signaling: A review.In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.Topotecan: a new topoisomerase I inhibiting antineoplastic agent.Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost.Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.Topoisomerases as anticancer targets.
P2860
Q33341835-B5743C1A-A9BC-4A7A-8ED2-76BBBFAEEE6EQ33366785-0EA2ECA9-7201-4316-B921-2D2D96CB23ACQ33374599-4B178D96-4324-4445-8B88-971CE57C057BQ33378252-7F155BF4-3A94-41A1-A356-5E68BFAA9AF8Q33379265-A2F493DD-6254-4592-9F49-9BD52F8E54E2Q33386456-2799B763-D434-4DED-91DB-637DF3315D18Q33386523-1EE42B1F-C72B-408E-A773-998FEA2AB874Q33398415-B5EF0C96-0EEB-4988-9C3F-A069789B586FQ34038021-67835BA1-1DB7-48CA-B8E9-172259670F58Q34177051-3DEBD6E3-0405-47BA-88DA-55E0665256E3Q34240913-859676A1-1F3A-403C-816F-101B52F0C984Q34616645-7C383290-16F8-4760-819D-E4CA1DC37EDEQ35101318-0258373B-E500-4341-997C-DBA6B268CE90Q35589197-6C0D230D-B0CD-4AD7-A221-DF81CE96EFA9Q35894574-081B5F5B-2666-40AB-ABAA-33DC89F857F9Q35968737-D97712F2-88F8-4BA5-9B70-AF90192F9455Q36027042-F7DF533F-6C03-4474-B057-D18137B8E97EQ36114881-BC354302-8D54-4442-81AA-4261E3BE39FBQ36431807-12DE5031-1360-4D98-B098-8CD6DF9330BFQ36488198-AC3D38DA-165E-49AA-BA30-1BB20C5680AEQ36671493-FFF08FE2-0E99-431B-B6F2-1FD9349CEAC5Q36689071-103FF5B9-33E0-4F54-BC17-1D02394F7539Q36696776-1416A393-B571-45E7-B5A3-DFA8EE9B98D3Q37229378-99A1F3AB-3D83-4D93-A429-002ABA8012C5Q39255529-BBAD8A27-4430-4B00-B2BD-149AE5D1B25EQ39263789-FADB6DE9-66E4-4182-934D-BB693C8D9C65Q39344635-73056CDA-9C28-477F-9869-BBE3321AFC53Q39400418-7E9508AF-B8C3-4D32-8034-2B6B828B935BQ40356343-78952B8A-633E-4D78-96EB-D76FC991101FQ42689189-46E2AF70-F5A3-4F79-BE7A-56FB15F0ADA0Q42862031-50DDA7C0-5CCC-4F83-98CB-89570B421495Q43922182-E10DCC8B-288B-4500-AC18-6178F00C2485Q44168595-834E3CC7-5A30-4E82-9499-C2C31B7EB7F1Q46929845-46896701-A66C-4E12-B79A-2603AD9C544AQ46963348-4C87BD1A-431F-4FA0-AD5B-F4810B82AD1FQ49832269-057EF9DC-CEAA-4707-B115-8AA7CC542210
P2860
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Topotecan, an active drug in t ...... large European phase II study.
@en
type
label
Topotecan, an active drug in t ...... large European phase II study.
@en
prefLabel
Topotecan, an active drug in t ...... large European phase II study.
@en
P2093
P1476
Topotecan, an active drug in t ...... large European phase II study.
@en
P2093
A J Lacave
G J Creemers
G Scarfone
J P Guastalla
P304
P356
10.1200/JCO.1996.14.12.3056
P407
P577
1996-12-01T00:00:00Z